Share

February 25, 2014; 82 (8) Special Article

Summary of evidence-based guideline update: Prevention of stroke in nonvalvular atrial fibrillation

Report of the Guideline Development Subcommittee of the American Academy of Neurology

Antonio Culebras, Steven R. Messé, Seemant Chaturvedi, Carlos S. Kase, Gary Gronseth
First published February 24, 2014, DOI: https://doi.org/10.1212/WNL.0000000000000145
Full PDF
Citation
Permissions

Comment

Downloads
29183

Share

This article has a correction. Please see:

Article Information

vol. 82 no. 8 716-724
DOI: 
https://doi.org/10.1212/WNL.0000000000000145
PubMed: 
24566225
Published By: 
Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology
Print ISSN: 
0028-3878
Online ISSN: 
1526-632X
History: 
  • Received May 21, 2013
  • Accepted in final form October 15, 2013
  • First Published February 24, 2014.
Copyright & Usage: 
© 2014 American Academy of Neurology

Author Information

    1. Antonio Culebras, MD, FAAN, FAHA,
    2. Steven R. Messé, MD, FAAN, FAHA,
    3. Seemant Chaturvedi, MD, FAAN, FAHA,
    4. Carlos S. Kase, MD, FAAN, FAHA and
    5. Gary Gronseth, MD, FAAN
  1. Antonio Culebras, MD, FAAN, FAHA,
    2. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. J Uriach & Co. S.A. Travel fund to make presentation at European Stroke Congress, Lisbon, May 2012.

    Editorial Boards:

    1. (1) Medlink, Associate Editor; (2) Medreviews, Associate Editor (discontinued).

    Patents:

    1. NONE

    Publishing Royalties:

    1. (1)Case studies in sleep neurology, 2012, Cambridge University Press, UK. (2) Sleep apnea, stroke and cardiovascular disease, 2013, Cambridge University Press, UK. (UK)

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. Clinical Stroke Research, Inc., NY.

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  2. Steven R. Messé, MD, FAAN, FAHA,
    3. Scientific Advisory Boards:

    1. (1) DSMB for an NIH/NINDS study of tPA in pediatric stroke

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. Atrial septal abnormalities (PFO, ASD, and ASA) and risk of cerebral emboli in adults, Antiplatelet therapy for secondary prevention of stroke, Up To Date, Inc. 2006 - present

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. Glaxo Smith Kline

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. WL Gore, local PI, 2009 - present Glaxo Smith Kline, National co-PI, 2013-present

    Research Support, Government Entities:

    1. 1) NIH/NIDDK, U01-DK060990, endpoint adjudication committee, 2007 - present. 2) NIH/NINDS, U01 NS40406-04, local PI, 2008 - 2013. 3) NIH/NHLBI, 1R01HL084375-01A2, subinvestigator in charge of neurologic assessments, 2009-2012, 4) NIH/NHLBI, HHSN268200800003C, back-up medical monitor, 2010-2013, 5) NIH/NHLBI UM1 HL088957-06, subinvestigator 2013 - present

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  3. Seemant Chaturvedi, MD, FAAN, FAHA,
    4. Scientific Advisory Boards:

    1. Executive Committee member for ACT I study

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. Editorial board member of NEUROLOGY and STROKE and contributing editor for NEJM Journal Watch Neurology

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. Consulting honoraria for Genentech, Boehringer-Ingelheim, Abbott Vascular, Thornhill research, Bristol Myers Squibb, WL Gore

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. Clinical studies supported by Daiichi, Astra Zeneca

    Research Support, Government Entities:

    1. NINDS for serving on grant review committee

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. Compensation for expert witness testimony

  4. Carlos S. Kase, MD, FAAN, FAHA and
    5. Scientific Advisory Boards:

    1. Lundbeck A/S; investigator, Desmoteplase in Acute Ischemic Stroke Trial (DIAS4): A randomized, double-blind, parallel-group placebo controlled phase III study to evaluate the efficacy and safety of desmoteplase in subjects with acute ischemic stroke.

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. Journal of Stroke and Cerebrovascular Diseases, Editorial Board member, 5 years

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. (1) NIH/NHLBI, Contract N01-HC-25195 (PI: Wolf; The Framingham Heart Study, Physical Examination, Testing, and Surveillance). Role: Co-Investigator. 10/01/08- 03/31/15. (2) NIH/NINDS, 2 R01-NS17950-27 (PI: Wolf; Precursors of Stroke Incidence and Prognosis). Role: Co-Investigator. 12/01/81-06/30/14. (3) NINDS, 2U01NS38529-04A1 (PI: Benavente; Secondary Prevention of Small Subcortical Strokes [SPS3]). Role: Co-Investigator. 06/01/03-01/31/12. (4) NINDS, 1 R01 NS 44876 01A2 (PI: Kernan; Insulin Resistance Intervention after Stroke Trial [IRIS]). Role: Co-Investigator. 09/01/04-08/31/11. (5) NINDS, 1580G HJ344 (PI: Kidwell; MR and Recanalization of Stroke Clots Using Embolectomy [MRRESCUE]). Role: Co-Investigator. 04/01/08-04/01/10

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  5. Gary Gronseth, MD, FAAN
    6. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. (1) Neurology Now, Editorial advisory board, Inception-Present (2) Neurology, Associate Editor, 2013-Present

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. Boehringer Ingelheim 2007-2011(Resigned Dec 2011)

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. American Academy of Neurology

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  1. From the Department of Neurology (A.C.), SUNY Upstate Medical University, Syracuse, NY; the Department of Stroke and Neurocritical Care (S.R.M.), Hospital of the University of Pennsylvania and the Pennsylvania Hospital, Philadelphia; the Stroke Program (S.C.), Wayne State University School of Medicine, Detroit, MI; the Department of Neurology (C.S.K.), Boston University School of Medicine and Boston Medical Center, Boston, MA; and the Department of Neurology (G.G.), University of Kansas Medical Center, Kansas City, KS.
  1. Correspondence to American Academy of Neurology: guidelines{at}aan.com
View Full Text

Article usage

Article usage: February 2014 to January 2019

AbstractFullPdfSource
Feb 2014445044934182Highwire
Mar 2014479962955560Highwire
Apr 2014170715951586Highwire
May 20149901171980Highwire
Jun 20145041162720Highwire
Jul 2014385953554Highwire
Aug 2014322762495Highwire
Sep 2014259765557Highwire
Oct 2014228744595Highwire
Nov 2014200692533Highwire
Dec 2014122651409Highwire
Jan 2015205658494Highwire
Feb 2015206634496Highwire
Feb 2015064pmc
Mar 2015234732516Highwire
Mar 201507444pmc
Apr 2015165638516Highwire
Apr 201504527pmc
May 2015144524415Highwire
May 201505628pmc
Jun 2015167563390Highwire
Jun 201505839pmc
Jul 2015136653398Highwire
Jul 201505126pmc
Aug 2015120736283Highwire
Aug 201504120pmc
Sep 2015127709406Highwire
Sep 201506942pmc
Oct 2015141738363Highwire
Oct 201504622pmc
Nov 2015148729316Highwire
Nov 201505235pmc
Dec 2015112382249Highwire
Dec 201502923pmc
Jan 2016132412310Highwire
Jan 201603933pmc
Feb 201689385340Highwire
Feb 201604228pmc
Mar 201688391350Highwire
Mar 201603219pmc
Apr 201669367263Highwire
Apr 201603320pmc
May 201659395269Highwire
May 201603220pmc
Jun 201683326270Highwire
Jun 201603724pmc
Jul 201644322236Highwire
Jul 201603316pmc
Aug 201673313389Highwire
Aug 201603215pmc
Sep 201666320299Highwire
Sep 201602511pmc
Oct 2016184417514Highwire
Oct 201602013pmc
Nov 2016160369372Highwire
Nov 201604319pmc
Dec 2016291299179Highwire
Dec 201604513pmc
Jan 2017308529232Highwire
Jan 20170165pmc
Feb 2017262416238Highwire
Feb 201703515pmc
Mar 2017330430288Highwire
Mar 201703916pmc
Apr 2017262364269Highwire
Apr 201792833pmc
May 2017305560180Highwire
May 2017113132pmc
Jun 2017261418226Highwire
Jun 2017143746pmc
Jul 2017290373153Highwire
Jul 2017114047pmc
Aug 2017300513191Highwire
Aug 2017174248pmc
Sep 2017357718213Highwire
Sep 201724444pmc
Oct 2017315663324Highwire
Oct 201794151pmc
Nov 2017228814224Highwire
Nov 2017155053pmc
Dec 20172618380Highwire
Jan 20183525356Highwire
Feb 20183518361Highwire
Mar 20182421760Highwire
Apr 20182422236Highwire
Apr 2018133544pmc
May 20182022046Highwire
Jun 20182516643Highwire
Jun 201882124pmc
Jul 2018616443Highwire
Aug 20181413847Highwire
Aug 2018134349pmc
Sep 20181120851Highwire
Oct 20181424597Highwire
Nov 20181618754Highwire
Dec 20181013961Highwire
Jan 2019921858Highwire

Cited By...

Disputes & Debates: Rapid online correspondence

Comment

NOTE: All contributors' disclosures must be entered and current in our database before comments can be posted. Enter and update disclosures at http://submit.neurology.org. Exception: replies to comments concerning an article you originally authored do not require updated disclosures.

  • Stay timely. Submit only on articles published within the last 8 weeks.
  • Do not be redundant. Read any comments already posted on the article prior to submission.
  • 200 words maximum.
  • 5 references maximum. Reference 1 must be the article on which you are commenting.
  • 5 authors maximum. Exception: replies can include all original authors of the article.
  • Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on Disputes & Debates

Compose comment

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
NOTE: The first author must also be the corresponding author of the comment.
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Publishing Agreement
NOTE: All contributors, besides the first/corresponding author, must complete a separate Disputes & Debates Submission Form and provide via email to the editorial office before comments can be posted.

Vertical Tabs

You May Also be Interested in

Back to top

Related Articles

Topics Discussed

Alert Me

Advertisement